Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

OBICETRAPIB AND CARDIOVASCULAR OUTCOMES: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFECT OF 10 MG OBICETRAPIB IN PARTICIPANTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) WHO ARE NOT ADEQUATELY CONTROLLED DESPITE MAXIMALLY TOLERATED LIPID-MODIFYING THERAPIES

Intervention/treatment:
OBICETRAPIB (TA-8995)
Medical condition:
CARDIOVASCULAR DISEASE
Protocol code:
TA-8995-304
Control number:
260653
Status:
Active, not recruiting
Approved:
February 17, 2022
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05202509
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
NEWAMSTERDAM PHARMA B.V.

Locations

British Columbia

Medical Arts Health Research Group - Kamloops
Kamloops, British Columbia, V2C 5T1
Medical Arts Health Research Group - North Vancouver
North Vancouver, British Columbia, V7M 2H4
The Medical Arts Health Research Group - Penticton
Penticton, British Columbia, V2A 5L5

Manitoba

Winnipeg Clinic
Winnipeg, Manitoba, R3C 0N2

Ontario

Brampton Clinical Trials
Brampton, Ontario, L4K 4M2
Centre de recherche clinique de Laval
Laval, Ontario, L1J2K1
Dr. James Cha
Oshawa, Ontario, L1J2K1
Institut Universitaire de Cardiologie et de Pneumologie De Quebec
Québec, Ontario, L8J 3W2
Kawartha Cardiology Clinical Trials
Peterborough, Ontario, K9J 0B2
KMH Cardiology & Diagnostic Centres - Hamilton
Stoney Creek, Ontario, L8J 3W2
KMH Cardiology & Diagnostic Centres - Mississauga
Mississauga, Ontario, K9J 0B2
LMC Diabetes & Endocrinology Ltd. - Thornhill
Concord, Ontario, L4K 4M2

Quebec

CardioVasc HR
Saint-Jean-sur-Richelieu, Quebec, J3A 1J2
Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Estrie -Centre hospitalier universitaire de Sherbrooke (CHUS)
Sherbrooke, Quebec, J1H 5N4
Diex Recherche Trois-Rivieres, Inc
Trois-Rivières, Quebec, G9A 4P3
Diex Recherche Victoriaville
Victoriaville, Quebec, G6P 6P6
Discovery Clinical Services, Ltd
Victoria, Quebec, J3A 1J2
Ecogene-21
Chicoutimi, Quebec, G7H 7K9
Did you find what you were looking for?